BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:13 PM
 | 
Jul 30, 2009
 |  BC Extra  |  Company News

FDA panel backs Saphris

FDA's Psychopharmacologic Drugs Advisory committee voted 12-0 that Saphris asenapine from Schering-Plough Corp. (NYSE:SGP) was safe and effective for acute treatment of manic or mixed episodes in adult...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >